CNTG Centogene N.V.

Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.

$5.92  +0.15 (2.60%)
As of 12/06/2021 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  Germany
Country of incorporation:  The Netherlands
IPO date:  11/07/2019
Outstanding shares:  22,117,643
Average volume:  39,531
Market cap:   $127,618,800
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    N1976T109
ISIN:        NL0014040206
Sedol:      BK824K5

---

Valuation   (See tab for details)

---

PE ratio:   -4.25
PB ratio:   3.63
PS ratio:   0.52
Return on equity:   -83.90%
Net income %:   -14.36%